David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that original research conducted using its PD2i algorithm to prospectively predict risk of sudden cardiac death was published in Therapeutics and Clinical Risk Management. Vicor Technologies is a biotechnology company focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i algorithm and software to stratify patients at risk of sudden cardiac death (SCD) and trauma victims in need of life saving intervention.
"Comparison of linear-stochastic and nonlinear-deterministic algorithms in the analysis of 15-minute clinical ECGs to predict risk of arrhythmic death" documents the comparative evaluation of nonlinear algorithms and conventional linear-stochastic measures of heartbeat series in low-to-high risk cardiac patients to prospectively predict risk of arrhythmic (sudden cardiac) death. Vicor's time-dependent, non-linear PD2i algorithm was demonstrated to be the comparatively superior test.
"We are gratified to have this study accepted for publication in Therapeutics and Clinical Risk Management," stated Mr. Fater. "Acceptance in this prestigious, peer-reviewed journal attests to the quality and rigor of the research in which the PD2i is involved. We are also heartened by the results, which attest once again to the PD2i's ability to prospectively predict those at risk of arrhythmic or sudden cardiac death with a high degree of accuracy and consistency," he concluded.